The cancer stem cell (CSC) model does not imply that tumours are generated from transformed tissue stem cells. The target of transformation could be a tissue stem cell, a progenitor cell, or a differentiated cell that acquires selfrenewal ability. The observation that induced pluripotency reprogramming and cancer are related has lead to the speculation that CSCs may arise through a reprogramming-like mechanism. Expression of pluripotency genes (Oct4, Nanog and Sox2) was tested in breast tumours by immunohistochemistry and it was found that Sox2 is expressed in early stage breast tumours. However, expression of Oct4 or Nanog was not found. Mammosphere formation in culture was used to reveal stem cell properties, where expression of Sox2, but not Oct4 or Nanog, was induced. Over-expression of Sox2 increased mammosphere formation, effect dependent on continuous Sox2 expression; furthermore, Sox2 knockdown prevented mammosphere formation and delayed tumour formation in xenograft tumour initiation models. Induction of Sox2 expression was achieved through activation of the distal enhancer of Sox2 promoter upon sphere formation, the same element that controls Sox2 transcription in pluripotent stem cells. These findings suggest that reactivation of Sox2 represents an early step in breast tumour initiation, explaining tumour heterogeneity by placing the tumour-initiating event in any cell along the axis of mammary differentiation.
Introduction
Many solid tumours, including breast cancer, exhibit a functional hierarchy of cells of which only a small subpopulation of stem-like cells give rise to the differentiated cells that make the bulk of the tumour (Al-Hajj et al., 2003) . Cancer stem cells (CSCs) occur as mimetic of normal tissue stem cells based on germ-line variation, epigenetic change and somatic mutation of stem cell signalling components, and then acquire more malignant phenotype based on accumulation of additional epigenetic and genetic alterations, and tumour-stromal interaction at the invasion front (Katoh, 2010) . However, the target cell for transformation that originates CSCs remains an unknown issue. In solid tumours the phenotypic definition of CSCs is rather loose with no single marker that unequivocally identifies that population. Such poor definition has prevented so far the needed study of clinical relevance of CSC content in tumour management. There are a number of reports using in vitro culture of tumour cells and animal models showing that CSCs are more resistant to conventional cancer therapies, therefore, placing these cells at the root of tumour recurrence and metastases. Several preliminary reports have indeed shown that this is the case with human cancer patients. In breast cancer, Li et al. (2008) showed that conventional chemotherapy increased the fraction of CD44 þ CD24
À cells in a neoadjuvant setting of advanced breast cancer patients and increased mammosphere formation in vitro. Tanei et al. (2009) have shown that paclitaxel and epirubicinbased chemotherapy enriches for aldehyde dehydrogenase-1-positive cells in breast tumours, another marker for CSCs (Ginestier et al., 2007) . In an attempt to associate CSC content and prognosis, the presence of CD44 þ CD24 À cells in clinical samples of breast cancer was not associated with aggressive tumour behaviour and poor clinical outcome (Abraham et al., 2005) , indicating that the definition of CSCs must be first clearly established before it can have clinical use. It is possible that different breast cancer subtypes rely on specific CSC populations and, therefore, more precise functional identification must be developed.
Reprogramming of adult terminally differentiated human cells into pluripotent stem cells capable of generating all cells in the body has attracted a great deal of attention. The production of these induced pluripotent stem cells requires the over-expression of four transcription factors Oct4, Sox2, Klf4 and c-Myc (Takahashi et al., 2007) , although Klf4 and c-Myc can be replaced by Lin28 and Nanog, and may even be dispensable (Meissner et al., 2007; Nakagawa et al., 2008; Okita et al., 2008; Kim et al., 2009) . The efficiency of this reprogramming process is extremely low and remains so far as an in vitro phenomenon as there is no evidence that it can naturally occur in vivo. The mechanisms underlying the reprogramming process are not well understood yet, however, the three main transcription factors Oct4, Sox2 and Nanog, called master regulators of pluripotency, have probed responsible for maintaining the undifferentiated state (Yamanaka, 2008) . Recently, the process of reprogramming and tumourigenesis (Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Utikal et al., 2009) have been linked as the p53 tumour suppressor, one of the main regulators of oncogenic transformation, controls the induction of pluripotency.
Sox genes encode a family of high-mobility group transcription factors that have critical roles in organogenesis. The functional specificity of different Sox proteins and the tissue specificity of a particular Sox factor are largely determined by the differential partnership with other transcription regulators, many of which have not yet been discovered. Recently, a number of links have been found between the Sox2 and human cancers. Sox2 has been found to be an immunogenic antigen in 41% of small cell lung cancer patients (Gure et al., 2000) and in 29% of meningioma patients (Comtesse et al., 2005) . Immunohistochemistry results suggest that Sox2 is involved in invasion and metastasis of pancreatic intraepithelial neoplasia (Sanada et al., 2006) , and may also be involved in gastric carcinogenesis (Li et al., 2004) and prostate cancers (Sattler et al., 2000) . Furthermore, Sox2 expression has been observed in 43% of basal cell-like breast carcinomas, suggesting a role in conferring a less differentiated phenotype (Rodriguez-Pinilla et al., 2007) . How Sox2 exerts its oncogenic potential is currently unknown.
In this work we investigated the relationship between pluripotency induction and breast cancer by examining the presence of pluripotency-related genes in human breast tumours. We did not observe expression of Oct4 or Nanog but we found expression of Sox2, which in turn was associated with early stages of tumour formation. We observed induction of Sox2 expression in tumour spheres from natural breast tumour cultures and breast carcinoma cell lines, suggesting a role in tumour stem cells. This role was further investigated by over-expressing and downregulating Sox2 expression, and it was found that Sox2 was necessary and sufficient to induce tumour sphere formation and tumour initiation in vivo. Regulation of Sox2 promoter activation probed to be dependent on the upstream enhancer and not on the core promoter, the same element that controls Sox2 expression in pluripotent stem cells.
Results
Expression of pluripotency-associated genes in natural breast tumours Oct4, Sox2 and Nanog are considered the master regulator genes of pluripotency and are switched off in adult tissues, except for Sox2 that is expressed in neural progenitors (Zappone et al., 2000) . However, reexpression of some or all of these genes has been found in several forms of human cancer. Using immunohistochemistry we checked expression of these genes in a panel of human breast tumour samples representative of the main breast cancer subtypes (Figure 1a) . We included staining for b-catenin as activation of the canonical Wnt signalling pathway, measured by nuclear localization of b-catenin, has been linked to mammary organogenesis (Zeng and Nusse, 2010) . For positive controls, we used sections of seminoma (for Oct4 and Nanog), non-small cell lung carcinoma (for Sox2) and colorectal carcinoma (for nuclear b-catenin). We did not observe expression of Oct4 or Nanog in any sample of our series (n ¼ 81 for Oct4 and n ¼ 71 for Nanog), nor nuclear b-catenin localization (n ¼ 64). However, we did observe Sox2-positive staining in B16% of the samples observed (n ¼ 158; Figure 1b1 ). Sox2 expression was previously reported in basal type breast cancer (Rodriguez-Pinilla et al., 2007) ; in our tumour series we observed Sox2-positive staining in tumour samples of all the major breast cancer subtypes ( Figure 1b2 ). Out of the 25 Sox2-positive tumours found, 13 showed infiltrating tissue structure by histological examination, while 12 tumours still retained in situ intra-ductal tumour component (Figure 1c) . Interestingly, those tumours that retained intra-ductal tumour component showed significantly (P ¼ 0.0347 by paired t-test) higher numbers of Sox2-positive cells there than in the infiltrating part, suggesting the presence of Sox2-positive cells in primitive areas of the tumour. Collectively, these data indicate that Sox2 may be expressed in the initial stages of tumour formation and it is lost as the tumour progresses towards advanced stages.
Sox2 is expressed in tumour spheres
Owing to the relevant role of Sox2 in pluripotency maintenance, we reasoned that Sox2 expression might be related to the presence of CSCs. We utilized the tumour sphere assay as a surrogate in vitro culture assay for tumour formation to investigate Sox2 expression in CSCs. In these culture conditions, CSCs are able to maintain stem-like properties such as tumour initiation, self-renewal and limited differentiation potential (Dontu et al., 2003; Ponti et al., 2005) . In our hands, B40% of tumour specimens produced viable sphere cultures with a frequency of sphere forming cells ranging between 0.1% and 1% of the total cell suspension (data not shown). We examined the expression of Sox2 in mammospheres from three tumour specimens using real-time PCR (RT-PCR). As seen in Figure 1d , Sox2 expression was observed in two out of three sphere cultures (specimens #207 and #208). We did not detect Sox2 expression in specimen #220 in uncultured tumour cells nor in tumour spheres. This result suggests that in (Livak and Schmittgen, 2001) . As a control, expression of Sox2 was assessed in total RNA obtained from a human embryonic stem cell culture (kindly provided by Dr R Sanchez Pernaute, Fundacio´n Inbiomed, Spain).
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O Leis et al Kuperwasser, 2008) . We therefore examined the ability of MCF7 breast carcinoma cells to grow as tumour spheres, measuring the ability to form mammospheres in serial passages and to make clonal spheres from single cells, reflecting the stem cell-like properties of selfrenewal and asymmetric division ( Figure 2a) . Indeed, the mammosphere assay has been demonstrated in MCF7 cells to enrich and propagate cells with enhanced tumour-initiating ability (Ao et al., 2011) . We used a commercial antibody array that allows assessing the expression of Oct4, Sox2, Nanog, and other (Figure 2d ). These results are consistent with the observations we obtained using the fresh breast tumour specimens. Next we stained mammospheres by immunofluorescence in different passages to locate Sox2-positive cells (Figure 2c ). We did not observe Sox2 staining from parental adherent cultures despite detecting positive expression in control extracts by immunoblotting, likely due to insufficient sensitivity of the immunofluorescence technique. We observed that only some of the cells in the tumour spheres stained positive for Sox2 (2.9% for T1, 5.7% for T2, 17.7% for T3, 12.1% for T4, 24.7% for T5 and 32.0% for T6) and those cells located preferentially to the periphery of the spheres. This effect was not due to insufficient access of the antibody to the centre of the spheres, as the inner cells were readily detected by E-Cadherin staining (Figure 2c lower right panel) . Therefore, it is tempting to speculate that those few Sox2-positive cells represent the CSCs and/or their immediate progeny. Essentially, the same results were obtained using T47D cells, a different breast carcinoma cell line (Supplementary Figure 1) .
Sox2 is necessary and sufficient for sphere formation
In order to test whether Sox2 was conferring stem cell properties to the breast carcinoma cells, we used the pCAGSS-Sox2-GFP construct to transiently express Sox2 in MCF7 cells. This vector allows the monitoring of plasmid activity by expression of the green fluorescent protein controlled by an IRES element. Expression of Sox2 induced the generation of approximately three-fold more spheres than the empty vector control (Figure 3a) . Interestingly, this effect was reversible and contingent to the activity of the plasmid, suggesting that the ectopic expression of Sox2 was responsible for the increase in sphere number. To test this possibility, we generated MCF7 cells with stable expression of Sox2 through lentiviral transfer (mCitrinie-P2A-Sox2 lentiviral vector) and observed a marked increase in sphere formation compared with mock-infected cells and those maintained in subsequent sphere passages (Figure 3b ). We then used RNA interference silencing with doublestranded RNA oligonucleotides (s13294 -si1-, s13295 -si2-and controls, Applied Biosystems, Carlsbad, CA, USA) to knockdown Sox2 expression for testing whether Sox2 expression was necessary to induce tumour spheres. Over 90% silencing was achieved with both siRNAs used, as confirmed by immunoblotting (Figure 3c ). When tested for mammosphere formation, we observed an evident reduction of sphere formation compared with control siRNA (50% reduction for -si1-and almost compete blockage for -si2-) indicating that Sox2 expression is necessary for mammosphere formation. We then tested the tumour initiation ability of MCF7 cells silenced for Sox2 expression in mouse xenograft assays (Figure 3d and Supplementary Figure 2) . As observed in Figure 3d , silencing of Sox2 expression with siRNA reduced the size of the tumours produced, as compared with siRNA control cells, indicating that Sox2 facilitates tumour initiation.
Sox2 promoter is induced upon sphere formation
Regulation of Sox2 expression is poorly understood. An area located between positions À528 and þ 238 from the transcription start site is considered as the core proximal promoter region (Miyagi et al., 2006) . Additionally, an upstream enhancer centred between À3444 and À3833 has an active role in controlling expression of Sox2 in the reprogramming of oligodendrocyte precursors (Kondo and Raff, 2004) and in Figure 3 Sox2 is sufficient and necessary for sphere formation. (a) Transient transfection of Sox2 with pCAGSS control or pCAGSSSox2 expression vectors. A schematic representation of the structure of the vector is shown. Twenty-four hours after transfection, cells were seeded in non-adherent conditions to allow for mammosphere formation and the number of spheres was counted after 7 days. Then spheres were disaggregated and reseeded to allow for T2 mammosphere formation. The number of T2 mammospheres was compared after 7 days. Expression of the plasmids was followed by green fluorescent protein expression measured in a flow cytometer (right panel) at every passage. (b) Stable expression of Sox2 was achieved through lentiviral transfer of Sox2-P2A-mCitrine lentiviral construct (described under Materials and methods). mCitrine-positive cells were sorted in a FACS Aria III cell sorter (BectonDickinson, Franklin Lakes, NJ, USA) to generate homogeneous cell cultures. Cells were seeded as described in (a) and the number of spheres was compared in each passage of Sox2 expressing cultures to that of mock-infected cultures. Right panel demonstrates Sox2 expression by immunoblotting using nuclear extracts from N-Tera2 cells as control and Sam68 expression as loading control. (c) siRNA-mediated silencing of Sox2 prevented mammosphere formation. Silencing was achieved using transient transfection of commercial siRNA oligonucleotides and appropriate controls. Forty-eight hours after transfection, cells were seeded in non-adherent conditions to allow for mammosphere formation and the number of spheres was compared after 7 days. Results are expressed as percentage of number of spheres compared with that of the control siRNA (black bars). Silencing of Sox2 was demonstrated by immunoblotting (right panel), as control Sam68 expression was not affected by siRNA treatment. A immunoblotting corresponding to a representative experiment of three is shown. Silencing quantification was achieved through scanning of the immunoblots and quantification of the digital images, results were expressed as percentage of Sox2 expression compared with the siRNA controls normalized by loading control (white bars). (d) Sox2 knockdown reduced tumour initiation in vivo. In all, 10 5 Sox2-silenced MCF7 cells (si2 sequence) or control siRNA cells were injected subcutaneously into both flanks of three mice per condition and tumour formation observed. Tumour size is expressed as tumour volume measured using a Vernier calliper as described in Materials and methods. Silencing of Sox2 was demonstrated by immunoblotting (not shown).
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O Leis et al pluripotent stem cells (Tomioka et al., 2002 ; see Figure 4a for a schematic representation of the Sox2 promoter). We transfected MCF7 and T47D cells with luciferase reporter vectors for the upstream distal enhancer and the core promoter to test whether induction of Sox2 protein was achieved through transcriptional activation of Sox2 promoter. As seen in Figure 4b and Supplementary Figure 2 , the Sox2 core promoter region reporter was not significantly activated upon sphere formation whereas the distal enhancer region was strongly activated (seven-fold on average). Taken together, these results suggest that reactivation of Sox2 expression in breast carcinoma cells upon sphere formation may be controlled at the promoter level, similarly as it is activated in pluripotent stem cells.
Discussion
The presence of CSCs in breast tumours is likely one of the main reasons why current oncologic therapies are poorly effective in preventing tumour progression, metastasis and recurrence (Shafee et al., 2008; Tanei et al., 2009; Cirenajwis et al., 2010) , so elimination of CSCs may become a necessary step for an effective cure. The target of malignant transformation could be a tissue stem cell, a progenitor cell, or a terminally differentiated cell that acquires, through mutations and epigenetic changes, the stem cell self-renewing property. To investigate this issue we examined the presence of stem-like cells by assessing the expression of the major stem cell pluripotency regulators, Oct4, Sox2 and Nanog (Jaenisch and Young, 2008) , in human natural breast tumours. We observed that Sox2 is expressed at the protein level in breast tumours, as expected (RodriguezPinilla et al., 2007; Chen et al., 2008) . However, Sox2 expression was more prevalent in the early stages of tumour development and in the ductal areas of tumours that still showed intact ductal structures, as is the case of lung cancer (Sholl et al., 2010) . During the preparation of this manuscript, Lengerke et al. (2011) reported the expression of Sox2 in early-stage breast carcinoma, similar to the results we have obtained. Interestingly, they showed higher expression of Sox2 in ductal carcinoma as opposed to invasive carcinoma (44% versus 28%). Together, these results indicate that Sox2 may be expressed in the initial phases of tumourigenesis and then is lost as the tumour develops. Spontaneous human breast tumours are predominantly differentiated luminal subtype (68%) while undifferentiated tumours comprise only 24% of the tumours (Callagy et al., 2003) . It is common to assume that the tumour phenotype reflects the cell of origin of that tumour, thus, most natural occurring tumours would be originated in the differentiated cells. Sox2 expression has been reported from normal mammary stem cells when cultured as mammospheres and lost as Figure 4 The distal enhancer of Sox2 promoter is induced upon sphere formation. (a) Schematic representation of Sox2 promoter structure indicating the proximal core promoter region and the location of the distal enhancer. Reporter constructs are specified. (b) In all, 5 mg of PGL3-Luc control, Sox2p-core-Luc and Sox2p-enhancer-Luc luciferase reporter vectors were transfected into MCF7 cells. Twenty-four hours after transfection, the culture was split in two, one part was seeded in 2D adherent culture and the other part was cultured in non-adherent culture conditions to allow mammosphere formation. After 48 h, cells were harvested and luciferase activity was compared, normalized by protein concentration in the extracts. Results are expressed as fold induction of sphere culture reporter activity above adherent culture control.
Sox2 activation in breast cancer stem cells
O Leis et al the cells differentiate in vitro (Simoes et al., 2010) . This assay is used as a stem-like functional assay that allows the propagation of mammary epithelial and breast tumour cells in an undifferentiated state based on their ability to proliferate in suspension (Dontu et al., 2003; Ponti et al., 2005; Farnie et al., 2007) and has been used for cancer stem-like specific drug screening in MCF7 cells (Zhou et al., 2007; Ao et al., 2011) . We did observe induction of Sox2 expression in mammospheres obtained from human breast tumour cell cultures, and from MCF7 and T47D cells. Moreover, we did not observe expression of any of the other pluripotencyassociated genes in MCF7-derived spheres, consistently with the results obtained in human tumours. Despite some reports claiming expression of Oct4 and Nanog in breast carcinoma cell lines, expression of several pseudogenes have been reported for both Oct4 and Nanog (Suo et al., 2005; Zhang et al., 2006; Cantz et al., 2007; Ambady et al., 2010) , therefore, particular care must be taken to avoid PCR amplification of those pseudogenes. We base our conclusions in antibodybased assays, thus, looking specifically at the protein level to avoid pseudogene detection. As opposed to spheres derived from glioma cell lines (Ghods et al., 2007) , only a few cells in the mammospheres were stained positive for Sox2, thus it is tempting to speculate that the tumour-initiating property resides in those cells. Further experiments will be needed to specifically isolate Sox2-positive cells and test their tumour generating ability. In order to verify the contribution of Sox2 to mammosphere formation, we over-expressed Sox2 and observed that Sox2 expression increased the ability to generate spheres. Interestingly, this effect was dependent on the continuous expression of Sox2 indicating that Sox2 expression was sufficient to induce this stem-like feature. Knockdown of Sox2 expression prevented the formation of spheres; thus, Sox2 expression was not only sufficient but also necessary to form spheres. Furthermore, when Sox2-silenced MCF7 cells were tested for tumour initiation in mouse xenograft models, we observed a marked reduction in the size of the tumours formed, suggesting that Sox2 participates in tumour initiation in vivo. This result is consistent with data reported on glioblastoma where Sox2 knockdown prevents glioma stem cells to initiate tumours (Gangemi et al., 2009) .
The process of in vitro pluripotency induction presents several parallelisms with tumour generation. Five groups independently (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009; Utikal et al., 2009) observed that p53 poses a barrier for pluripotency induction. Mutations that inactivate the p53 tumour suppressor network occur in most natural human tumours, thus, remarkable similarities must exist between the genetic and epigenetic processes involved in the generation of cancer, and the acquisition of a less differentiated phenotype and self-renewal ability in induced pluripotency. Loss of p53 confers stem-like properties in committed progenitors in the haematopoietic system (Akala et al., 2008) , and loss of p53 increases the size of the mammary repopulating compartment in mice by 10-fold, suggesting that p53 may act as a regulator of stem cell self-renewal in vivo (Cicalese et al., 2009 ). Therefore, it is possible that the acquisition of the self-renewal ability of CSCs arises by some of the mechanisms shared with those involved in pluripotency reprogramming, in cells that harbour permissive mutations, such as inactivation of the p53 pathway. This mechanism explains the generation of CSCs from committed progenitors with limited differentiation potential responsible for the heterogeneous subtypes observed in natural tumours. We did not observe induction of Oct4 or Nanog, therefore, a full pluripotency programme cannot be established. The ability of non-stem cells to convert to CSCs implies intrinsic plasticity at the level of the cell of origin of the tumours. In this regard, transformation of an immortalized breast epithelial cell line (MCF10A) by the oncogene Src generated cells with features of CSCs only when interleukin-6 was added to the medium, suggesting that CSCs can be originated from non-CSC transformed cells (Iliopoulos et al., 2011) . Similar results were obtained attending to in vitro culture of floating human mammary epithelial cells, where cells with stem-like features arise from FACS (fluorescence-activated cell sorting)-sorted differentiated epithelial cells (Chaffer et al., 2011) . We propose that spontaneous dedifferentiation in vivo may involve reactivation of one or more pluripotency-associated factors, such as Sox2 expression in breast cancer, consistent with our observations. What the mechanisms for reactivation are, how are they different from a full pluripotency programme and how contextual signals from the microenvironment (such as induction of EMT (Mani et al., 2008) participate in this process, will shed light into how tumours are initiated and how to control this process.
How Sox2 expression is reactivated remains unclear. Sox2 promoter consists of two main regulatory regions, the core promoter located at the transcription initiation site and an upstream distal enhancer. Our results indicate that it is precisely this upstream distal enhancer that is activated in mammospheres, as a luciferase reporter with this enhancer is strongly induced upon sphere formation. The upstream enhancer was strongly activated in undifferentiated embryonic stem cells and its activity was lost upon differentiation (Tomioka et al., 2002) , it is the same behaviour as observed in multipotent neural stem cells (Miyagi et al., 2004; Miyagi et al., 2006) . In embryonic stem cells, a non-consensus octamer-binding site in the enhancer is occupied by Oct3/4-Sox2 dimers, however, as we did not observe Oct4 expression in mammospheres, a different mechanism must operate. Recently, a possible implication of the transcription factor NF (nuclear factor)-kB has been proposed, although no direct regulation was reported (Liu et al., 2010) . Kondo and Raff (Kondo and Raff, 2004) demonstrated that Sox2 reactivation in the conversion of oligodendrocyte precursors depends on the recruitment of the protein Brca1 to this enhancer, together with the chromatin remodelling protein Brm. These complexes have a critical role in the maintenance of the pluripotent state by regulating occupancy of pluripotency-related gene promoters (Kidder et al., Sox2 activation in breast cancer stem cells O Leis et al 2009). As Brca1 is a well-known tumour suppressor gene that when mutated predisposes women to breast and ovarian cancer (Miki et al., 1994) , a possibility is that loss of Brca1 mediates tumour initiation by losing the control on Sox2 expression, establishing a direct link between Sox2 expression and breast cancer initiation. Nevertheless, this model needs further testing.
Materials and methods
Tumour sample collection A total of 158 cases of breast tumour samples were collected at the Pathology Department of Onkologikoa (San Sebastian, Spain) from patients that underwent curative surgical resection (for tumour data see Supplementary File 1). Institutional review board approval and expressed informed consent were obtained from all patients before sample collection. Formalinfixed paraffin-embedded sections of tumours were stained routinely with haematoxylin-eosin and reviewed by two senior pathologists (RR and KE) to determine the histological type according to WHO breast carcinoma histological classification criteria (2003) Cell culture Fresh tumour samples were cut up into small pieces and minced completely using scissors. Tumour pieces were enzymatically digested with Collagenase IA (Sigma, St Louis, MO, USA) at the concentration of 2 mg/ml and incubated at 37 1C for 1 h. Then, the digested sample was filtered through a 40-mm cell strainer and washed with Hank's balanced salt solution. For sphere formation, cells were cultured at an initial density of 50 000 cells/ml in serum-free Dulbecco's modied Eagle's medium supplemented with 1% L-glutamine, 1% penicillin/ streptomycin, 30% F12 (Sigma), 2% B27 (Invitrogen, Carlsbad, CA, USA), 20 ng/ml EGF (Sigma) and 20 ng/ml FGFb (Invitrogen) in non-adherent culture plates. For subsequent sphere formation, cells were seeded at a density of 5 000 cells/ml. MCF-7 and T47D breast carcinoma cell lines were obtained directly from the ATCC (Manassas, VA, USA) and grown in Dulbecco's modied Eagle's medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma) at 37 1C in a 5% CO 2 incubator. For mammosphere formation, single-cell suspensions were plated in six-well tissue culture plates covered with poly-2-hydroxyethyl-methacrylate (Sigma) to prevent cell attachment at a density of 1000 cells/ml in the medium described above. The medium was made semi-solid by the addition of 0.5% Methylcellulose (R&D Systems, Minneapolis, MN, USA) to prevent cell aggregation. Mammospheres were collected by gentle centrifugation after 7 days, and dissociated enzymatically (5 min in 1:1 trypsin/Dulbecco's modied Eagle's medium solution at 37 1C) and mechanically by passing through a 25G needle. Single cells were replated at a density of 1000 cells/ml for subsequent passages.
Plasmids and antibodies pCAGSS-Sox2 and empty pCAGSS control expression vectors were kindly provided by A Matheu (Medical Research Council, London, UK). For immunoblotting, immunofluorescence and immunohistochemistry anti-human Sox2 polyclonal antibody (Neuromics GT15098), anti-human Oct4 polyclonal antibody (Santa Cruz sc-8629, Santa Cruz, CA, USA), antihuman Nanog polyclonal antibody (R&D Systems AF1997), anti-human b-catenin monoclonal antibody (Millipore 05665, Billerica, MA, USA), anti-human E-cadherin polyclonal antibody (Cell Signaling FAB18381A, Danvers, MA, USA) and anti-human Sam68 polyclonal antibody (Santa Cruz sc-333) were used as indicated.
Immunohistochemistry
Immunohistochemical staining on tumour sections was performed using Dako Autostainer automatic universal slide stainer. Antibodies, dilutions, antigen-retrieval methods and scoring systems for ER, PR, HER2, CK5/6, EGFR and ki67 are part of the routine histopathological determination at the Pathology Department of Onkologikoa (San Sebastian, Spain). Cases were considered positive for Sox2 when any unequivocal neoplastic cell displayed definite nuclear staining. Positive (as indicated) and negative controls were included in each slide run.
Real-time PCR
Total RNA was obtained using RNAqueous-Micro kit (Ambion, Austin, TX, USA) following manufacturer's instructions. Power SYBER Green PCR Master Mix (Applied Biosystems) was used to amplify the corresponding genes with primers for human Sox2 (forward: 5 0 -GGGAAATGGGAGGGGTGCAA AAGAGG-3 0 , reverse: 5 0 -TTGCGTGAGTGTGGATGGGGA TTGGTG-3 0 ). Amplification of human GAPDH (Hs_GAP DH_2_SG QuantiTect Primer Assay QT01192646, Qiagen, Hilden, Germany) was used as loading control. RT-PCR was performed in a StepOnePlus Real-Time PCR System.
Immunofluorescence
Mammospheres were collected by centrifugation in a Cytospin (Thermo, Waltham, MA, USA) onto glass slides. Slides were fixed in 4% paraformaldehyde for 1 h at room temperature in wet chamber, washed twice in phosphatebuffered saline (PBS) and allowed to permeabilize for 1 h at room temperature with PBS þ 0.3% Triton X-100 and blocked. Slides were then incubated with primary antibodies overnight and washed thrice in PBS, and appropriate fluorofore labelled secondary antibodies were added at a dilution of 1/250. Hoescht 33342 dye (Sigma, St Louis, MO, USA) was used to reveal nuclear DNA. Immunofluorescence was visualized in a Zeiss LSM510 confocal laser-scanning microscope (Zeiss, Jena, Germany).
Immunoblotting Nuclear extracts (prepared as in Martin et al. (2001) ) were blotted onto a polyvinylidene fluoride membrane (Millipore) and blocked in Tris-buffered saline with 0.2% Tween 20 and 5% milk powder. Immunoblotting for Sox2 and Sam68 was carried out using primary antibodies at a 1:2000 dilution and appropriate secondary antibody coupled to horseradish peroxidase (1:10 000 dilution). SuperSignal West Pico Chemiluminescent Substrate developing kit (Thermo) was used to reveal the relevant bands.
Transfection, gene silencing and lentiviral gene transfer For transient transfection, MCF-7 cells were cultured in sixwell tissue culture plates and transfected when at 70% confluence using Lipofectamine Plus or Oligofectamine Mouse xenograft assays Female 6-week-old athymic nude mice (Balb/c Nu/Nu) were purchased from Charles River, and were housed in specifically designed pathogen-free isolation animal facility. All animal procedures were performed in accordance with institutional animal care and use guidelines. For injection, MCF7 cells of each condition were resuspended in 10 ml of the same media at a concentration of 1 Â 10 6 cells/ml. Mice were subcutaneously inoculated with the MCF7 cell line in 200 ml of culture medium with matrigel in both mammary fat pads. In all, 10 5 MCF7 cells with Sox2 knockdown were inoculated in the right mammary fat pad, with their respective control in the left mammary fat pad. Mice were weighed and the inoculation sites were inspected by palpation at weekly intervals. When tumours become detectable manually, the growth rates were determined by weekly measurement of two diameters of the tumour with a Vernier calliper. The tumour volume was estimated as the volume of an ellipse using the following formula: V ¼ 4/3 Â (a/2) Â (b/2)2, where 'a' and 'b' correspond to the longest and shortest diameter, respectively. Animals were euthanized when their tumours were harvested, fixed and embedded in paraffin.
Luciferase reporter assays MCF-7 cells were transfected with 5 mg of pGL3 Luc control (Promega, Madison, WI, USA), pGL3-Sox2p-enhancer-Luc (kindly provided by T Kondo, RIKEN, Japan) or pGL3-Sox2p-core-Luc (kindly provided by JM Sanchez-Puelles, CIB, Madrid, Spain) reporter plasmids using Lipofectamine Plus (Invitrogen). Luciferase activity was measured in duplicate with the Glomax 20/20 luminometer (Promega) and the results were expressed as fold induction above control.
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